Trial Profile
A multi-Centre, Exploratory Trial to Assess the Mechanisms of Molecular Activity, Safety and Tolerability of One Dose Level of FE 999301 by Intravenous Infusions in Patients with Active Inflammatory Bowel Disease (IBD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2021
Price :
$35
*
At a glance
- Drugs Olamkicept (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms FUTURE; Future-010
- 02 Mar 2021 Results published in the Gastroenterology
- 16 Jul 2018 Status changed from recruiting to completed.
- 13 Sep 2016 New trial record